Bionor Readies Key Trial To Prove 'Shock And Kill' Could Lead To Functional HIV Cure
This article was originally published in Scrip
Bionor Pharma ASA has met the primary endpoint of its REDUC HIV 'shock and kill' trial, which tested a potential vaccine to cure HIV/AIDS.
You may also be interested in...
Hepatitis C is effectively cured. Could this success be replicated in another serious chronic viral condition ‒ HIV? Abivax, which last year abandoned its hepatitis B lead program, has bounced back with data suggesting a 'functional cure' for HIV is more than just a pipe dream.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.